Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab and Lenalidomide in Refractory/Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
NCT06723457Phase 2Recruiting
- Sponsor
- Reem Karmali
- Start
- Jul 2025
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab and lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Reem Karmali. Primary endpoint: Complete Response Rate at 6 months. Started Jul 2025; status: recruiting.
02
Drugs
epcoritamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06723457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723457.